8-K: Lumexa Imaging Reports Strong Q4, Full Year 2025 Results

Lumexa Imaging announced preliminary Q4 and full year 2025 financial results, showcasing strong Adjusted EBITDA growth and reiterating its 2026 guidance.

Summary

• Consolidated revenues for Q4 2025 reached $267.7 million, an increase of 7.9% from $248.0 million in Q4 2024.
• Full year 2025 consolidated revenues were $1.023 billion, up 7.8% from $948.9 million in 2024.
• Adjusted EBITDA for Q4 2025 grew by 18.6% to $63.8 million, with a 23.8% margin.
• Full year 2025 Adjusted EBITDA increased by 14.6% to $230.2 million, achieving a 22.5% margin.
• The company reduced its leverage by two turns, from 5.5 times to 3.5 times, resulting in over $50 million in annual cash savings.
• Net loss for Q4 2025 was $28.7 million, compared to a $25.1 million net loss in Q4 2024.
• Full year 2025 net loss significantly improved to $47.1 million, down from a $94.1 million net loss in 2024.
• Lumexa Imaging added ten new imaging facilities in 2025, comprising nine de novo centers (six wholly owned, three joint ventures) and one acquired site.
• Same-center advanced volume growth was 12.7% for consolidated and 9.2% for system-wide in Q4 2025.
• The company reiterated its full year 2026 guidance, expecting consolidated revenues of $1.045 to $1.097 billion and Adjusted EBITDA of $234 to $242 million.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing positively due to strong operational growth, significant balance sheet improvement through leverage reduction, and confident reiteration of future guidance, despite the preliminary nature of the results and a higher Q4 net loss.

Positives

• Strong consolidated revenue growth of 7.9% in Q4 2025 and 7.8% for the full year 2025.
• Significant Adjusted EBITDA growth of 18.6% in Q4 2025 and 14.6% for the full year 2025, demonstrating operational efficiency.
• Achieved a two-turn reduction in leverage, from 5.5 times to 3.5 times, leading to more than $50 million in annual cash savings and a strengthened balance sheet.
• Substantial improvement in full year net loss, reducing from $94.1 million in 2024 to $47.1 million in 2025.
• Opened a record number of ten new imaging facilities in 2025, including nine de novo centers, setting the stage for future growth.
• Experienced robust same-center advanced volume growth, with 12.7% for consolidated and 9.2% for system-wide in Q4 2025.
• Successfully returned in-network with a large payer in New Jersey, contributing to strong Adjusted EBITDA growth.

Negatives

• Reported a net loss of $28.7 million for Q4 2025, an increase from the $25.1 million net loss in Q4 2024.
• The financial results are preliminary, unaudited, and subject to final review and adjustment, meaning final results could differ materially.

Risks

• The financial information for Q4 and full year 2025 is preliminary and unaudited, subject to change, and final results may differ materially after year-end closing procedures and audit completion.
• Forward-looking statements regarding future financial performance and operating results may not materialize, and actual results are subject to risks and uncertainties that could cause them to differ materially from projections.
• Reliance on non-GAAP financial measures (Adjusted EBITDA, Adjusted EPS) which are not calculated in accordance with GAAP and may not be comparable to similarly titled measures used by other companies.

Future Outlook

Lumexa Imaging reiterated its full year 2026 guidance, expecting consolidated revenues between $1.045 billion and $1.097 billion. Adjusted EBITDA is projected to be between $234 million and $242 million, which includes approximately $7 million in public company costs not incurred in 2025. The company also provided guidance for Adjusted EPS of $0.71 to $0.77 per share, reflecting continued growth and margin expansion supported by durable demand tailwinds and the ongoing shift to outpatient care.

Management Comments

• Caitlin Zulla, CEO, stated, 'The fourth quarter of 2025 marked a strong close to an important year for Lumexa Imaging, with continued momentum across the business.'
• Ms. Zulla highlighted that 'Strong Adjusted EBITDA growth was driven by advanced imaging volumes, ramping new de novo centers, and our return in-network with a large payer in New Jersey.'
• Ms. Zulla also noted, 'We strengthened our balance sheet, reducing leverage by two turns, and opened a record number of de novo centers during the year, setting the stage for future growth.'
• Looking ahead, Ms. Zulla commented, 'Our 2026 outlook reflects continued growth and margin expansion, supported by durable demand tailwinds and the ongoing shift to outpatient care.'
• Ms. Zulla concluded, 'With a focused strategy centered on same-center growth, geographic expansion, and advanced imaging, we believe Lumexa Imaging is well positioned to deliver sustained, profitable growth while expanding access to high-quality, lower-cost imaging for patients, providers, and payors.'

Industry Context

StockSavvy.ai notes that Lumexa Imaging's performance aligns with broader healthcare trends, particularly the ongoing shift towards outpatient care settings. As one of the nation's largest providers of outpatient imaging services, the company is well-positioned to capitalize on durable demand tailwinds in this sector, which typically offers lower-cost alternatives to hospital-based services.

Comparison to Industry Standards

• The company's focus on advanced imaging volumes (MRI and CT modalities) and geographic expansion through de novo centers is consistent with growth strategies observed among leading outpatient healthcare providers aiming to capture market share in high-demand, specialized services.
• The reduction in leverage from 5.5x to 3.5x is a significant balance sheet improvement, positioning Lumexa Imaging more favorably compared to highly leveraged peers in the healthcare services sector, enhancing financial flexibility for future investments or market volatility.
• The reiterated 2026 guidance, despite including new public company costs, suggests confidence in continued operational execution and market demand, a positive signal in an industry often subject to regulatory and reimbursement pressures.

Legal Proceedings

• The reconciliation of GAAP to non-GAAP measures includes adjustments for 'Litigation and settlements' costs, which are described as matters not related to core operations, but no specific details on ongoing proceedings are provided.

Related Party Transactions

• The balance sheet lists 'Accounts receivable, related party' of $18.893 million in 2025 and $23.308 million in 2024.
• The statement of operations includes a 'Gain on imaging center sold, related party' of $2.294 million in 2024.

Stakeholder Impact

• Shareholders: Potential positive impact due to strong revenue and Adjusted EBITDA growth, significant leverage reduction, and strategic expansion, which could drive long-term value.
• Patients, Providers, and Payors: Positive impact through expanded access to high-quality, lower-cost imaging services due to the opening of new centers and the company's strategic focus on outpatient care.

Next Steps

• Lumexa Imaging will host a conference call to discuss its fourth quarter and full year 2025 results, as well as its 2026 outlook, on March 26, 2026, at 8:30 a.m. ET.

Key Dates

Recommendation

Lumexa Imaging demonstrates strong operational momentum with robust revenue and Adjusted EBITDA growth, coupled with a significant reduction in leverage that strengthens its financial position. The strategic expansion through new de novo centers and the reiteration of positive 2026 guidance suggest continued growth potential. While the Q4 net loss increased, the substantial improvement in full-year net loss and overall positive trends indicate a company executing well on its strategy, making it an attractive long-term investment.

Keywords

Lumexa Imaging, LMRI, outpatient imaging, financial results, Q4 2025, full year 2025, 2026 guidance, Adjusted EBITDA, revenue growth, leverage reduction, de novo centers, healthcare services, medical imaging